Attack on Qui Nhon MARKET TIME Base
On 22 December 1967, the MARKET TIME
support base at Qui Nhon was attacked by an estimated platoon of enemy sappers.
The well coordinated attack was initiated at 2329 when a Coastal Group 22
command junk, located in the middle of a nest of junks, was blown up and sunk.
The attack continued throughout the early morning hours of the 23rd and resulted
in two Navy men killed and 16 others wounded, two of whom died later during
treatment. Material damage resulting from the attack included extensive damage
to the CPO quarters and light damage to the mess hall and enlisted barracks.
Seven enemy were killed (four probable) during the attack and the following
ordnance was captured: 10 Chinese communist fragmentation grenades, five
grenades that were improvised from 61mm mortar hears, two Chinese communist
copies of the Russian AK-47 assault rifle, and one automatic pistol. The Qui
Nhon base continued to receive harassing fire through the 27th of the month.
Orlistat Hexal Online Bestellen
5-5 stars based on
Orlistat is used for managing obesity in overweight adults.
Alli orlistat online bestellen
In a letter to patients and their caregivers, the company offers no indication that any of the above medications will actually cause a heart attack.
"There is no evidence that statins provide a benefit in the management of high cholesterol levels," the company said. "Their use in patients with high cholesterol levels has been found to be unnecessary and cause harm."
The company, which sells a generic version of vardenafil (Viagra) in the UK and elsewhere, added that the drug is "of very low risk" and "has been used to prevent heart attacks Orlistat 60mg $103.21 - $1.15 Per pill for many years."
For years, doctors in the United States have advised patients with high cholesterol to avoid or limit the use of statins to lower it through other means like losing weight. Now, however, some doctors are changing their stance.
Doctors also have been taking a look at other drugs that target cholesterol, including niacin, which is a B vitamins supplement and has a long-held "heart-protecting" reputation.
But the new evidence also points to one drug -- ruxolitinib, which treats several types of cancer -- that could represent a turning point in the history of cholesterol medicine.
The drug has a low risk of causing heart attack, a new research article in The England Journal of Medicine said.
Ruxolitinib, which was discovered in 1990 by researchers at Massachusetts General Hospital and a pharmaceutical company called Merck Sharp & Dohme, was given approval by the United States Food and Drug Administration earlier this month.
It is the first statin drug that carries a clear cardiac risk.
The authors of new study said that it "could be a turning point for the treatment of high cholesterol and lead to a reduction in cardiovascular risks."
"The FDA has made a serious error by deciding on a pathway that gives statins an undeserved and unjustified 'clean bill of health,' " they claimed. "We urge the agency to reverse its decision."
Dr. David Acheson, who chairs the department of cardiovascular medicine at the University of Vermont Medical Center, cautioned against being over optimistic about the safety and effectiveness of statins.
"The drug industry is currently using the data that suggests it does not cause a heart attack as cover for the fact that it can have effects might help a subset of users to have a stroke or heart attack," he told CBS News.
However, he is certain that other statin drugs have similar beneficial effects.
"This drug has the best potential to reduce our risk for stroke by any drug currently on the market," he said. "I have seen data in the hundreds of people that confirm a potential benefit in patients who are on statins also have been involved in a heart attack or stroke."
He added that it will be difficult to convince cardiologists that all statins are as dangerous some had initially thought and that has led some of them to suggest giving a "tough love" to patients with high cholesterol.
Doctors are not required by the FDA to list specific risks or benefits in their prescribing instructions for drugs, and the agency has said t